Here is a summary of the data for Utah : Share of all patients who take a GLP-1: 0.7% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.4% Share of female patients with an obesity diagnosis who take a GLP-1: 5.1% Share of GLP-1 users that are female: 60.4% For reference, here are the statistics for the entire United States: Share of all patients who take a GLP-1: 1.0% Share of patients with an obesity diagnosis who take a GLP-1: 4.8% Share of male patients with an obesity diagnosis who take a GLP-1: 4.2% Share of female patients with an obesity diagnosis who take a GLP-1: 5.2% Share of GLP-1 users that are female: 64.7% For more information, a detailed methodology, and complete results, see U.S
They contain the same drug, so taking both would mean doubling up on semaglutide, which raises the risk of side effects without added benefit
New York, NY (2014)
Our leadership team proposed gatekeeping with [an online weight-loss management program.] And theyre like, no, we cant afford this at all, so were cutting off [coverage for GLP-1 agonists for weight loss]
It occurs in two forms, known as D and L, but only L-carnitine is active in the body and is the form found in food
You might and you might not
